Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

ABSTRACT:

Objective

Use of growth hormone is associated with side effects, including insulin resistance. The objective of this study was to determine whether tesamorelin, a stabilized growth hormone-releasing hormone analogue, would alter insulin sensitivity or control of diabetes.

Design

A 12-week randomized, placebo-controlled study of 53 patients with type 2 diabetes. Three treatment groups: placebo, 1 and 2 mg tesamorelin.

Measurements

Fasting glucose, glucose and insulin from oral glucose tolerance test, glycosylated hemoglobin (HbA1c), home blood glucose, insulin-like growth factor-1, and lipids.

Main outcome measure

Relative insulin response following oral ingestion of glucose.

Results

No significant differences were observed between groups in relative insu

SUBMITTER: Clemmons DR 

PROVIDER: S-EPMC5472315 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature